| __timestamp | Madrigal Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 15746000 | 72471000 |
| Thursday, January 1, 2015 | 13392000 | 89204000 |
| Friday, January 1, 2016 | 9290000 | 106010000 |
| Sunday, January 1, 2017 | 7672000 | 137905000 |
| Monday, January 1, 2018 | 15293000 | 159888000 |
| Tuesday, January 1, 2019 | 22648000 | 158425000 |
| Wednesday, January 1, 2020 | 21864000 | 200677000 |
| Friday, January 1, 2021 | 37318000 | 304759000 |
| Saturday, January 1, 2022 | 48130000 | 377221000 |
| Sunday, January 1, 2023 | 108146000 | 336361000 |
Igniting the spark of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. From 2014 to 2023, Madrigal Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. have shown contrasting strategies in optimizing these costs. Madrigal's SG&A expenses grew from approximately $15.7 million in 2014 to $108.1 million in 2023, marking a significant increase of nearly 588%. In contrast, Supernus started with $72.5 million in 2014 and reached $336.4 million by 2023, a 364% rise. While both companies have seen substantial growth in expenses, Supernus consistently spent more, peaking at $377.2 million in 2022. This data suggests that while Madrigal is catching up, Supernus has maintained a higher expenditure, possibly reflecting different strategic priorities or market conditions. Understanding these trends can provide valuable insights into each company's operational focus and market positioning.
Cost Management Insights: SG&A Expenses for GSK plc and Madrigal Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Madrigal Pharmaceuticals, Inc.
Genmab A/S and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.